Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether a diuretic drug called amiloride is capable of increasing renal salt excretion and thereby decrease blood pressure in diabetic patients with kidney disease. Our hypothesis states that amiloride is capable of reducing blood pressure in these patients and thus decrease the cardiovascular risk associated with diabetic kidney disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern Denmark
• Collaborators: Danish Heart Foundation; Odense University Hospital; Region of Southern Denmark; The Ministry of Science, Technology and Innovation, Denmark
• Treatments: Amiloride; Epithelial Sodium Channel Blockers; Triamterene

Criteria

Inclusion Criteria:

• Type 1 diabetes

• Negative pregnancy test at inclusion and taking contraceptive medication

• One group with diabetic nephropathy and overt proteinuria

• One normoalbuminuric group without nephropathy

• Creatinine clearance > 40 ml/min

Exclusion Criteria:

• Type 2 diabetes

• Receiving amiloride, glucocorticoids, aldosterone or spironolactone

• Clinically relevant organic or systemic disease including malignancy